drugset / Trial / NCT05676242
A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis
RandomizedParallel-groupDouble-blindTreatment
Summary
To observe the safety and effectiveness of long-term use of jaktinib hydrochloride tablets in the treatment of moderate and severe atopic dermatitis
Timeline
- Start
- 2023-01-11
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Jaktinib | Unknown | 75 mg | Oral |
| Subject | Jaktinib | Unknown | 100 mg | Oral |